Crystal Gardner-Martin, MD
Nephrology · Livonia, MINPI 1447244280
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $98,509 of the $139,909 with a category attached, or 70.4%. 25 manufacturers reported payments, led by Bayer at 36.9% of the total. Reporting peaked in 2022 at $57,990 and has fallen 90.2% since, to $5,671 in 2025. Among nephrology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 491 payments — averaging $284.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$52K
- Vifor Pharma, Inc.$48K
- Travere Therapeutics, Inc.$22K
- Fresenius USA Marketing, Inc.$13K
- AstraZeneca$1K
- Boehringer Ingelheim$598
- plus $4K from 19 others
What the payments were for
- Consulting fees$8,5956%
- Speaking & faculty fees$98,50970%
- Travel & lodging$19,83614%
- Food & beverage$12,7799%
- Education$1900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 71 | $51,593 |
| Vifor Pharma, Inc. | 84 | $48,258 |
| Travere Therapeutics, Inc. | 73 | $21,543 |
| Fresenius USA Marketing, Inc. | 29 | $12,695 |
| AstraZeneca(2 entities) | 56 | $1,450 |
| Boehringer Ingelheim | 36 | $598 |
| Otsuka America Pharmaceutical, Inc. | 19 | $552 |
| Amgen(2 entities) | 22 | $495 |
| Aurinia Pharma U.S., Inc. | 17 | $370 |
| Novartis | 14 | $305 |
| GSK | 11 | $287 |
| Novo Nordisk | 3 | $262 |
| Mallinckrodt Hospital Products Inc. | 8 | $239 |
| Akebia Therapeutics Inc | 8 | $231 |
| Mallinckrodt Enterprises LLC | 5 | $202 |
| Ardelyx, Inc. | 5 | $197 |
| OPKO Pharmaceuticals, LLC | 9 | $155 |
| Calliditas Therapeutics US Inc. | 7 | $146 |
| ANI Pharmaceuticals, Inc. | 4 | $89 |
| Sanofi | 3 | $63 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $60 |
| Ultragenyx Pharmaceutical Inc. | 2 | $42 |
| Apellis Pharmaceuticals, Inc. | 2 | $35 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$139,909 in reported general payments places this provider in the 95th percentile of 325 nephrology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 195 | $179,759 |
| OzempicSemaglutide | 144 | $140,834 |
| JardianceEmpagliflozin | 114 | $104,380 |
| VelphoroSucroferric Oxyhydroxide | 28 | $80,273 |
| KerendiaFinerenone | 46 | $48,812 |
| VeltassaPatiromer Calcium Sorbitex | 33 | $32,851 |
| LokelmaSodium Zirconium Cyclosilicate | 27 | $27,776 |
| TrulicityDulaglutide | 20 | $25,064 |
| EliquisApixaban | 32 | $20,934 |
| Sevelamer Carbonate | 80 | $19,345 |
| LinzessLinaclotide | 16 | $19,234 |
| RybelsusSemaglutide | 12 | $18,393 |
| InvokanaCanagliflozin | 15 | $18,013 |
| EntrestoSacubitril/Valsartan | 15 | $13,064 |
| Cinacalcet Hcl | 32 | $12,249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,450 | $207,535222 claims |
| Novo NordiskOzempic, Rybelsus | $262 | $159,227156 claims |
| Boehringer IngelheimJardiance | $598 | $104,380114 claims |
| Fresenius USA Marketing, Inc.Velphoro | $12,695 | $80,27328 claims |
| BayerKerendia | $51,593 | $48,81246 claims |
| NovartisEntresto | $305 | $13,06415 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $89 | $77915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 325 nephrology providers in Michigan.
Other nephrology in Livonia
- Michael MisuracaLivonia$10K
- Mark MarroneLivonia$8K
- Victoria GolasLivonia$6K
- Jason BiedermanLivonia$6K
- Kelly MercierLivonia$6K
- Talanki ViswanathLivonia$5K
- Alexander YevzlinAnn Arbor$1.1M
- Muwaffaq SalamehBay City$164K
- Laura MarianiAnn Arbor$150K
- Katherine KwonSaint Joseph$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.